Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: The example of the novel anticancer agent ABT-751

Pharmacogenetics and Genomics

Volumn 23, Issue 7, 2013, Pages 374-381

  Innocenti, Federico ^a,c   Rez, Jacqueline Rami ^c   Obel, Jennifer ^c   Xiong, Julia ^b   Mirkov, Snezana ^c   Chiu, Yi Lin ^b   Katz, David A ^b   Carr, Robert A ^b   Zhang, Wei ^c   Das, Soma ^d,e   Adjei, Araba ^f,g   Moyer, Ann M ^f   Chen, Pei Xian ^g   Krivoshik, Andrew ^b   Medina, Diane ^b   Gordon, Gary B ^b   Ratain, Mark J ^c,d,e   Sahelijo, Leonardo ^b   Weinshilboum, Richard M ^f   Fleming, Gini F ^c,e   Bhathena, Anahita ^b   more..

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b ABBVIE INC   (United States)

^c Department of Medicine ^*  (United States)

^d Committee on Pharmacology and Pharmacogenomics ^*  (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f MAYO CLINIC   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

ABT 751; Drug Development; Drug Metabolism; Pharmacogenetics; Phase I; Sulfotransferase; Udp Glucuronosyltransferase

Indexed keywords

DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 2B7; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1;

AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; DRUG DOSE ESCALATION; FEMALE; GENOTYPE; GLUCURONIDATION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SULFATION;

EID: 84879130143     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283623e81     Document Type: Article

References (35)

1. Rubin EH, Gilliland DG. Drug development and clinical trials-the path to an approved cancer drug. Nat Rev Clin Oncol 2012; 9:215-222.
2. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005; 5:447-458.
3. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyagani N, Kitoh K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: Inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997; 57:3208-3213.
4. Yamamoto K, Noda K, Yoshimura A, Fukuoka M, Furuse K, Niitani H. Phase I study of E7010. Cancer Chemother Pharmacol 1998; 42:127-134.
5. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005; 11: 6615-6624.
6. Fox E, Maris JM, Cohn SL, GoodspeedW, Goodwin A, Kromplewski M, et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol 2010; 66:737-743.
7. Rudin CM, Mauer A, Smakal M, Juergens R, Spelda S, Wertheim M, et al. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2011; 29:1075-1082.
8. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: Results of a phase 1 study. Clin Cancer Res 2006; 12:2834-2840.
9. Rudek MA, Zhao M, He P, Messermith WA, Baker SD. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies. J Pharm Biomed Anal 2006; 42:253-260.
10. Sheweita SA, Tilmisany AK. Cancer and phase II drug-metabolizing enzymes. Curr Drug Metab 2003; 4:45-58.
11. Hebbring SJ, Moyer AM, Weinshilboum RM. Sulfotransferase gene copy number variation: Pharmacogenetics and function. Cytogenet Genome Res 2008; 123:205-210.
12. Nowell S, Falany CN. Pharmacogenetics of human cytosolic sulfotransferases. Oncogene 2006; 25:1673-1678.
13. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2006; 3:136-158.
14. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009; 101:708-720.
15. Purba HS, Maggs JL, Orme ML, Back D, Park BK. The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: Formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol 1987; 23: 447-453.
16. Innocenti F, Iyer L, Ramirez J, Green MD, Ratain MJ. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 2001; 29:686-692.
17. Yoder Graber AL, Ramirez J, Innocenti F, Ratain MJ. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics 2007; 17:619-627.
18. Adjei AA, Weinshilboum RM. Catecholestrogen sulfation: Possible role in carcinogenesis. Biochem Biophys Res Commun 2002; 292:402-408.
19. Lindsay J,Wang LL, Li Y, Zhou SF. Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 2008; 9:99-105.
20. Johnson GA, Baker CA. Sulfation of minoxidil by human platelet sulfotransferase. Clin Chim Acta 1987; 169:217-227.
21. Cleland WW. Computer programmes for processing enzyme kinetic data. Nature 1963; 198:463-465.
22. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-1388.
23. Sawyer MB, Innocenti F, Das S, Cheng C, Ramirez J, Pantle-Fisher FH, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003; 73: 566-574.
24. Carlini EJ, Raftogianis RB, Wood TC, Jin F, Zheng W, Rebbeck TR, et al. Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 2001; 11:57-68.
25. Michels J, Ellard SL, Le L, Kollmannsberger C, Murray N, Tomlinson Guns ES, et al. A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Ann Oncol 2009; 21:305-311.
26. Katz DA, Murray B, Bhathena A, Sahelijo L. Defining drug disposition determinants: A pharmacogenetic-pharmacokinetic strategy. Nat Rev Drug Discov 2008; 7:293-305.
27. Food and Drug Administration. Guidance for industry: Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. (DRAFT). US Department of Health and Human Services Food and Drug Administration; Center for Drug Evaluation and Research (CDER); February 2012. Available at: Http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf [Accessed 9 May 2012].
28. Iyer L, King CD,Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847-854.
29. Ramirez J, Iyer L, Journault K, Belanger P, Innocenti F, Ratain MJ, et al. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res 2002; 19:588-594.
30. Kang SP, Ramirez J, House L, Zhang W, Mirkov S, Liu W, et al. A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics 2010; 20:638-641.
31. Kamdem LK, Liu Y, Stearns V, Kadlubar SA, Ramirez J, Jeter S, et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 2010; 70:854-869.
32. Yu X, Dhakal IB, Beggs M, Edavana VK, Williams S, Zhang X, et al. Functional genetic variants in the 30-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. Toxicol Sci 2010; 118:391-403.
33. Strassburg CP, Nguyen N, Manns MP, Tukey RH. Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol 1998; 54:647-654.
34. Mizuma T. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 2009; 378:140-141.
35. Wiener D, Fang JL, Dossett N, Lazarus P. Correlation between UDPglucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone glucuronidation phenotype in human liver microsomes. Cancer Res 2004; 64:1190-1196.